NCT02614872View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 26, 2016

Primary Completion Date

April 11, 2019

Study Completion Date

May 7, 2019

Conditions
Transplantation, Lung Rejection
Interventions
DRUG

GLASSIA® and Institution standard of care (SOC)

Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)

Trial Locations (1)

Unknown

Pulmonary Institute - Rabin Medical Center, Petah Tikva

All Listed Sponsors
lead

Kamada, Ltd.

INDUSTRY

NCT02614872 - Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation | Biotech Hunter | Biotech Hunter